Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
25,601 results
  • A Review of Antithrombotic Treatment in Critical Limb Ischemia After Endovascular Intervention. [Review]
    Cardiol Ther 2019Gupta A, Lee MS, … Reddy S
  • Endovascular intervention is often used to treat critical limb ischemia (CLI). Post-intervention treatment with antiplatelet and/or anticoagulant therapy has reduced morbidity and mortality due to cardiovascular complications. The purpose of this review is to shed light on the various pharmacologic treatment protocols for treating CLI following endovascular procedures. We reviewed the literature …
  • Early-cannulation ePTFE arteriovenous access grafts are associated with a low incidence of pseudoaneurysm formation. [Journal Article]
    Ann Vasc Surg 2019MacKenzie DJ, Nash J, … Kingsmore DB
  • CONCLUSIONS: Pseudoaneurysm formation occurs less frequently in AcusealTM grafts compared with historical data for standard PTFE grafts. Pseudoaneurysm formation did not occur in any graft within the first 13 months following implantation; suggesting early-cannulation prior to incorporation is not in itself a risk factor for pseudoaneurysm development. Poor needling, venous stenosis, inadequate surveillance and anticoagulation/dual antiplatelet therapy are remediable factors, and graft preservation is possible. AcusealTM is a robust graft with lower rates of pseudoaneurysm formation on long-term follow up than standard PTFE grafts.
  • Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome. [Journal Article]
    Res Pract Thromb Haemost 2019; 3(4):684-694Grosdidier C, Blanz KD, … Canault M
  • Antiplatelet therapy through inhibition of the adenosine diphosphate (ADP)/P2Y12 pathway is commonly used in the treatment of acute coronary syndrome (ACS). Although efficient in preventing platelet activation and thrombus formation, it increases the risk of bleeding complications. In patients with ACS receiving platelet aggregation inhibitors, that is, P2Y12 blockers (n = 923), we investigated t…
New Search Next